证券日报网讯 2月9日，药易购在互动平台回答投资者提问时表示，公司始终将合规运营放在首位，持 续优化治理结构，强化内部控制和合规管理，督促董高忠实、勤勉履职，从根本上保护投资者利益，致 力于为股东创造长期、稳定的价值回报。关于公司后续是否投保董高责任险，将结合该险种的保险内容 情况以及市场概况考虑，并严格按照法律法规相关规定履行相关信息披露义务。 （文章来源：证券日报） ...

医药行业数字化转型加速，医药供应链领域正经历结构性变革，竞争转向科技赋能与模式创新。作为A 股创业板医药供应链龙头，国内首家上市的医药产业 互联网 企业 药易购 （股票代码：300937）立足行 业趋势，在升级核心医药供应链业务的同时，持续加码创新业务，通过科技赋能构筑长期竞争壁垒，其 前瞻性布局不仅契合行业发展方向，更具备极强的资本市场长期布局价值。 我国医药行业正处于高质量发展转型期，2026年AI医疗拐点确立，行业展望指出"AI赋能+基本面反 转"将成为核心增长引擎，这为医药供应链企业的创新升级提供了广阔空间。"十四五"期间药品供应链 市场规模持续扩容，2024年销售额达2.95万亿元，其 中药 品零售市场6500亿元。商务部等9部门印发相 关意见，推动药品零售行业数字化、规范化发展，为药易购创新布局提供了重要政策支撑，也进一步打 开了药易购等公司新业务的资本想象空间。 随着医药科技进步、政策完善以及AI医疗拐点确立，行业集中度将持续提升，具备科技优势、新赛道 布局前瞻的企业将获得更大发展空间，也将成为资本市场的核心关注标的。药易购的创新布局精准契合 行业方向，新赛道多点开花，长期价值增长确定性强，有望 ...

Financial Projections - The company expects a net profit of between 2.8 million to 4.2 million CNY for the year 2025, representing a decline of 74.32% to 82.88% compared to the previous year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 1.6 million to 2.4 million CNY, reflecting a decrease of 80.60% to 87.07% year-on-year[5]. Profitability Challenges - The decline in profitability is attributed to changes in the overall market environment, industry policies, and shifts in retail structure and consumer behavior[4]. - Increased income tax expenses are due to the company's ineligibility for preferential tax rates under the Western Development policy, leading to higher tax liabilities[6]. - The company has terminated some loss-making projects, but residual costs from these projects continue to negatively impact current profits[6]. - The company has recognized impairment losses on goodwill based on the requirements of accounting standards for the fiscal year 2025[6]. Business Development - The company is in the early stages of developing new business areas, with ongoing R&D and market expansion costs that have not yet generated significant revenue[4]. Financial Reporting - The financial data presented is preliminary and has not been audited by the accounting firm, with detailed figures to be disclosed in the 2025 annual report[7].

Core Viewpoint - The A-share market for pharmaceutical retail stocks experienced a collective rise, driven by new government measures aimed at enhancing pharmaceutical services and encouraging retail drug sales [1] Group 1: Market Performance - Pharmaceutical retail stocks such as Renmin Tongtai and Yifeng Pharmacy hit the daily limit up, while Luyuan Pharmaceutical rose over 7%, Daclin increased over 6%, and Jiuzhoutong gained over 5% [1] - Other notable performers included Zhongyao Holdings, Yaoyigou, Haiwang Biological, Hefuchina, and Shuyupingmin, all rising over 4% [1] Group 2: Government Measures - The Ministry of Commerce and nine other departments issued a document proposing improvements in pharmaceutical services, enhancing pharmacy service capabilities, and promoting prescription circulation to improve the purchasing experience [1] - Measures include optimizing outpatient service coordination for designated retail pharmacies and encouraging retail drug companies to participate in centralized drug procurement [1] - The government is promoting horizontal mergers and acquisitions among retail drug companies and encouraging the sale of innovative drugs and reference preparations through retail channels [1] - There is an emphasis on encouraging e-pharmacy platforms to open data interfaces and strengthen the monitoring of price linkages between online and offline drug retail prices and provincial procurement platform prices [1]

Group 1 - The core viewpoint of the article highlights a collective rise in A-share pharmaceutical commercial stocks, driven by government initiatives to enhance pharmaceutical services and retail drug sales [1] - The Ministry of Commerce and nine other departments issued a document proposing measures to improve pharmaceutical services, enhance pharmacy service capabilities, and promote prescription circulation to improve the purchasing experience [1] - The document encourages pharmaceutical retail companies to engage in horizontal mergers and acquisitions, and to innovate in drug sales channels, including the sale of innovative drugs and reference preparations through retail pharmacies [1] Group 2 - Notable stock performances include: - Renmin Tongtai (人民同泰) with a rise of 10.04% and a total market value of 72.43 billion [2] - Yifeng Pharmacy (益丰药房) increasing by 10.02% with a market cap of 301 billion [2] - Luyuan Pharmaceutical (鹭燕医药) up by 7.76% with a market value of 70.13 billion [2] - Dacelin (大参林) rising by 6.63% with a market cap of 242 billion [2] - Jiuzhoutong (九州通) increasing by 5.27% with a market value of 282 billion [2] - Other companies showing significant gains include Zhongyao Holdings (重药控股) up by 4.89%, Yaoyigou (药易购) up by 4.42%, and Haiwang Biological (海王生物) up by 4.41% [2]

Core Viewpoint - The retail pharmacy sector experienced a significant rise in stock prices following the release of a government policy aimed at promoting high-quality development in the pharmaceutical retail industry [1] Group 1: Policy Impact - On January 22, the Ministry of Commerce and nine other departments issued guidelines to encourage horizontal mergers and acquisitions in the pharmaceutical retail sector [1] - The policy aims to optimize the business environment for retail pharmacies, including streamlining the application process for drug operating licenses for consolidated chain or standalone pharmacies [1] - It promotes the integration of wholesale and retail operations to enhance supply chain efficiency and reduce operational costs through shared logistics resources and collaborative quality management systems [1] Group 2: Market Outlook - According to Guojin Securities, leading compliant pharmacy chains are expected to benefit first from the ongoing regulatory push for industry standardization [1] - Companies that have proactively adjusted their store operations are projected to see a marginal recovery in revenue by the third quarter of 2025 [1] - Some leading companies are beginning to explore non-pharmaceutical product offerings, which could become a significant source of profit if they exceed expectations in performance [1]

Group 1 - The company, Yiyigou (300937.SZ), stated that it currently has no relationship with WiNGPT and has not engaged in any collaboration with Ant Group's Aifu in the medical AI sector [1]

Core Viewpoint - The company emphasizes the importance of artificial intelligence and advanced technologies in enhancing its core business and has established a subsidiary to strengthen its digital ecosystem [2] Group 1: Company Initiatives - The company has set up a subsidiary named Shutan Artificial Intelligence to enhance its digital capabilities [2] - The company has completed the localization deployment of DeepSeek, which is part of its efforts to promote internal digital transformation and external ecosystem empowerment [2] - These initiatives aim to improve the efficiency of the industry chain and empower upstream and downstream partners, thereby enhancing the company's long-term competitiveness [2]

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.19% on January 15, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - Notable gainers included: - RunDa Medical (603108) with a closing price of 20.04, up 1.83% and a trading volume of 700,800 shares [1] - LiuYao Group (603368) closed at 18.58, up 0.60% with a trading volume of 79,700 shares [1] - LaoBaiXing (603883) closed at 16.11, up 0.50% with a trading volume of 226,200 shares [1] - Significant decliners included: - Huaren Health (301408) closed at 23.81, down 19.99% with a trading volume of 491,100 shares [2] - ShangYu PingMin (301017) closed at 18.50, down 13.75% with a trading volume of 373,900 shares [2] - YaoYiGou (300937) closed at 37.40, down 11.79% with a trading volume of 121,400 shares [2] Capital Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 990 million yuan from institutional investors, while retail investors had a net inflow of 977 million yuan [2] - The table of capital flow indicates that: - LaoBaiXing (603883) had a net inflow of 46.10 million yuan from institutional investors [3] - JiuZhouTong (600998) had a net inflow of 40.43 million yuan from institutional investors [3] - RunDa Medical (603108) had a net inflow of 37.80 million yuan from institutional investors [3]

Core Viewpoint - Yaoyigou's stock price has increased by 5.12% on January 14, reaching 42.48 CNY per share, with a trading volume of 263 million CNY and a turnover rate of 10.47%, resulting in a total market capitalization of 4.064 billion CNY. The stock has risen for three consecutive days, with a cumulative increase of 14.22% during this period [1] Company Overview - Sichuan Hezhong Yaoyigou Pharmaceutical Co., Ltd. is located at 18 Youlian Street, Jin Niu District, Chengdu, Sichuan Province, and was established on April 28, 2007. The company was listed on January 27, 2021. Its main business involves the wholesale and retail of pharmaceutical products in the outpatient market [1] - The revenue composition of the main business is as follows: pharmaceuticals (chemical drugs) account for 99.27%, while other products (supplements) account for 0.73% [1] Shareholder Information - According to data from the top ten circulating shareholders of Yaoyigou, a fund under Nuoan Fund ranks among the top shareholders. The Nuoan Multi-Strategy Mixed A Fund (320016) entered the top ten circulating shareholders in the third quarter, holding 564,000 shares, which represents 0.92% of the circulating shares. It is estimated that the fund has gained approximately 1.1675 million CNY today, with a total floating profit of 2.8369 million CNY during the three-day increase [2] - The Nuoan Multi-Strategy Mixed A Fund (320016) was established on August 9, 2011, with a latest scale of 1.855 billion CNY. Year-to-date returns are 5.21%, ranking 2743 out of 8838 in its category; the one-year return is 88.18%, ranking 316 out of 8089; and since inception, the return is 247.2% [2] - The fund manager of Nuoan Multi-Strategy Mixed A is Kong Xianzheng, who has been in the position for 5 years and 50 days. The total asset scale of the fund under his management is 5.608 billion CNY, with the best fund return during his tenure being 93.39% and the worst being -16.74% [2]